Therefore, while AFP production is a marker of aggressive disease, further investigation into its role and the associated resistance mechanisms may identify novel therapeutic targets to improve treatment responses in patients with AFP-producing pancreatic cancer. This evidence concerns the gene AFP and familial pancreatic carcinoma.